The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Artificial intelligence (AI) -powered spatial analysis of tumor-infiltrating lymphocytes (TIL) for prediction of prognosis in stage II-III resectable colon cancer.
 
Yoojoo Lim
Employment - IMBdx; Lunit
Stock and Other Ownership Interests - Lunit
 
Songji Choi
No Relationships to Disclose
 
Hyeon Jeong Oh
No Relationships to Disclose
 
Sanghoon Song
Employment - Lunit
 
Sukjun Kim
Employment - Lunit
 
Heon Song
Employment - Lunit
Stock and Other Ownership Interests - Vuno
 
Seonwook Park
Employment - Lunit
Stock and Other Ownership Interests - Lunit; Lunit (Inst)
Research Funding - Lunit (Inst)
 
Ji-Won Kim
No Relationships to Disclose
 
Jin Won Kim
Consulting or Advisory Role - AstraZeneca; BeiGene Beijing; BeiGene Beijing; BeyondBIO; Bristol-Myers Squibb/Celgene; Eisai; GC Cell; MSD; Ono Pharmaceutical; Roche; Sanofi; Servier; TCUBEit
 
Jee Hyun Kim
Honoraria - AstraZeneca; Eisai; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi
Consulting or Advisory Role - Bixink; Daiichi Sankyo/Astra Zeneca; Eisai; Novartis; Pfizer; Roche; Yuhan
Research Funding - Ono Pharmaceutical (Inst); Roche (Inst)
 
Minsu Kang
No Relationships to Disclose
 
Sung-Bum Kang
No Relationships to Disclose
 
Duck-Woo Kim
No Relationships to Disclose
 
Heung-Kwon Oh
No Relationships to Disclose
 
Hye Seung Lee
No Relationships to Disclose
 
Keun-Wook Lee
Honoraria - Boryung; JW Pharmaceutical; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Metafines; MSD; Ono Pharmaceutical; Sanofi/Aventis; Vifor Pharma
Research Funding - ABL Bio (Inst); ALX Oncology (Inst); Amgen (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); GC Pharma (Inst); Genome & Company (Inst); Ildong Pharmaceutical (Inst); InventisBio (Inst); Leap Therapeutics (Inst); LSK BioPharma (Inst); Macrogenics (Inst); MedPacto (Inst); Merck KGaA (Inst); MSD (Inst); Oncologie (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Trishula Therapeutics (Inst); Y-BIOLOGICS (Inst); Zymeworks (Inst)